St

Eton is awaiting final FDA acceptance of its pediatric study protocol (PSP) for ET-104. The product’s NDA is expected to be submitted once. agreement is reached on the PSP. ET-103. Eton is in discussions with the FDA regarding the product’s bioequivalence data results to ensure compliance with FDA requirements prior to. submission of the NDA. ................
................